激光生物学报
激光生物學報
격광생물학보
ACTA LASER BIOLOGY SINICA
2005年
5期
368-372
,共5页
李步洪%杨浦文%张镇西%谢树森
李步洪%楊浦文%張鎮西%謝樹森
리보홍%양포문%장진서%사수삼
血啉甲醚%鼻咽癌细胞%荧光强度%浓度
血啉甲醚%鼻嚥癌細胞%熒光彊度%濃度
혈람갑미%비인암세포%형광강도%농도
Hematoporphyrin monomethyl ether%nasopharyngeal carcinoma cells%Fluorescence intensity%concentration
利用激光诱导荧光方法实验测定了新型光敏剂血啉甲醚(Hematoporphyrin Monomethyl Ether, HMME)在鼻咽癌细胞株CNE中的时间分布和浓度变化规律.实验结果表明,鼻咽癌细胞株CNE的荧光光谱中的两个特征峰615 nm和675 nm证实了鼻咽癌细胞对HMME的选择性特异吸收.HMME在鼻咽癌细胞中的潴留浓度在混合培养后的140分钟达到最大值.当用于培养鼻咽癌细胞的HMME药物浓度低于32 μg/ml时,测量得到的相对荧光光谱强度与HMME浓度呈现出很好的线性关系,通过拟合方程可以间接确定在给定注射剂量条件下鼻咽癌细胞中所潴留HMME的浓度.结果可以为HMME在光动力学诊断与治疗中的临床应用提供理论依据和剂量参考.
利用激光誘導熒光方法實驗測定瞭新型光敏劑血啉甲醚(Hematoporphyrin Monomethyl Ether, HMME)在鼻嚥癌細胞株CNE中的時間分佈和濃度變化規律.實驗結果錶明,鼻嚥癌細胞株CNE的熒光光譜中的兩箇特徵峰615 nm和675 nm證實瞭鼻嚥癌細胞對HMME的選擇性特異吸收.HMME在鼻嚥癌細胞中的潴留濃度在混閤培養後的140分鐘達到最大值.噹用于培養鼻嚥癌細胞的HMME藥物濃度低于32 μg/ml時,測量得到的相對熒光光譜彊度與HMME濃度呈現齣很好的線性關繫,通過擬閤方程可以間接確定在給定註射劑量條件下鼻嚥癌細胞中所潴留HMME的濃度.結果可以為HMME在光動力學診斷與治療中的臨床應用提供理論依據和劑量參攷.
이용격광유도형광방법실험측정료신형광민제혈람갑미(Hematoporphyrin Monomethyl Ether, HMME)재비인암세포주CNE중적시간분포화농도변화규률.실험결과표명,비인암세포주CNE적형광광보중적량개특정봉615 nm화675 nm증실료비인암세포대HMME적선택성특이흡수.HMME재비인암세포중적저류농도재혼합배양후적140분종체도최대치.당용우배양비인암세포적HMME약물농도저우32 μg/ml시,측량득도적상대형광광보강도여HMME농도정현출흔호적선성관계,통과의합방정가이간접학정재급정주사제량조건하비인암세포중소저류HMME적농도.결과가이위HMME재광동역학진단여치료중적림상응용제공이론의거화제량삼고.
Time dependence and concentration of cellular selective uptake of new photosensitizer Hematoporphyrin monomethyl ether (HMME) in human nasopharyngeal carcinoma cell line CNE have been studied and determined by incubated CNE cells with HMME. Experimental results show that the peak emission fluorescence at the wavelength of 615 and 675 nm characterized the selective accumulation of HMME in CNE cells. The curve for time dependence of HMME in CNE cells indicate that the highest uptake peak appear in about 140 mins after incubation. When the concentration of HMME for incubated CNE cells under 32 μg/ml, the fluorescence intensity versus HMME concentration reveals an obvious linearity. These results can be used to improve the efficiency of photodynamic therapy and the accuracy of optical diagnosis for nasopharyngeal carcinoma with HMME.